Today AQILION AB announced that the extraordinary general meeting of the project company Adenovir Pharma AB resolved to liquidate the company. According to the decision, liquidation will begin on November 1, 2019. Adenovir Pharma developed an antiviral medication (APD-209) to treat and potentially even to prevent the contagious eye disease epidemic keratoconjunctivitis (EKC), which is […]
Martin Johansson holds a doctorate in organic chemistry from Lund University, Sweden, where he is currently an Associate Professor at the Center for Analysis and Synthesis. He has almost 20 years’ experience of medicinal chemistry and commercial drug discovery. Martin has previously held positions as senior researcher in AstraZeneca’s organization for Discovery R&D, in Södertälje, […]
http://aqilion.com/wp-content/uploads/2019/03/aqilion_logo_main.png00Aqilionhttp://aqilion.com/wp-content/uploads/2019/03/aqilion_logo_main.pngAqilion2019-08-22 08:01:412019-10-22 20:10:05Aqilion hires Martin Johansson as medicinal chemistry expert
In March of 2018, AQILION AB (formerly Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB) carried out a directed issue of “units.” Each unit consisted of one (1) share and two (2) warrants. At that time, Aqilion raised SEK 100 million through subscription for shares. All outstanding warrants have now been converted to shares, which […]
http://aqilion.com/wp-content/uploads/2019/03/aqilion_logo_main.png00Aqilionhttp://aqilion.com/wp-content/uploads/2019/03/aqilion_logo_main.pngAqilion2019-07-18 08:01:222019-10-23 16:37:57Aqilion receives SEK 100 million through conversion of outstanding warrants
https://aqilion.com/wp-content/uploads/2019/10/bio-europe.png226808Aqilionhttp://aqilion.com/wp-content/uploads/2019/03/aqilion_logo_main.pngAqilion2019-10-22 09:15:082019-10-23 06:26:5011 November 2019: BIO-Europe in Hamburg
Aqilion identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market.
The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner.
Aqilion prefers projects aimed at niche markets. Specialty medications and orphan drugs are of particular interest.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.
Other external services
We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Vimeo and Youtube video embeds: